Molecular Partners Announces Participation in Scientific Conferences

Rhea-AI Summary

Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has announced its participation in several key conferences in June 2022, highlighting developments in their DARPin therapeutics aimed at treating various diseases. At the European Hematology Association Conference, they will present data on MP0533, a T-cell engager targeting tumors. Additionally, Novartis will showcase preclinical data on ensovibep, a COVID-19 treatment. Presentations also include discussions on ensuring safety and efficacy for AML therapies. Further details can be accessed via their official website.

Positive

• Participation in major conferences increases visibility and credibility in the biotech sector.
• Presentation of MP0533 data demonstrates progress in cancer treatment research.
• Collaboration with Novartis on ensovibep could enhance development prospects against COVID-19.

Negative

• None.

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 10, 2022 (GLOBE NEWSWIRE) --  Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that members of its team will participate in the European Hematology Association (EHA) Conference as well as other conferences in June. In addition, Novartis, the global license owner of ensovibep, will present preclinical data from the anti-SARS-CoV-2 program.

Conferences Details:

• Poster; European Hematology Association (EHA) Conference
  • Title: MP0533, a New Multispecific DARPin CD3 Engager Targeting Three Tumor Associated Antigens, Induces Specific T-cell Activation and AML Tumor Killing in vivo
  • June 9-12, Vienna
• Poster (Novartis); American Society for Microbiology (ASM Microbe)
  • Title: SARS-CoV-2 Omicron and Multi-variant Neutralization Activity of Ensovibep: A DARPin Therapeutic Candidate For Treatment Of Covid-19
  • June 9-13, Washington, DC
• Poster; Dissecting Evolution and Heterogeneity of Single Cancer Cells
  • Title: Characterization of Tumor Infiltrating Dendritic Cells at the Single Cell Level
  • June 12-17, Easton, MA
    

Additional recent presentations:

• Talks; Antibody Engineering & Therapeutics Europe
  • Title: Ensovibep, a SARS-CoV-2 Multi-Variant Neutralizing DARPin Therapeutic
  • Title: A Triple-targeting DARPin T-cell Engager Approach to Improve Safety and Efficacy for the Treatment of AML
  • June 7-9, 2022, Amsterdam

Presentations will be made available as available, through the Molecular Partners website
        
About Molecular Partners AG 
Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. www.molecularpartners.com; Find us on Twitter - @MolecularPrtnrs

FAQ

What is the significance of Molecular Partners' participation in the EHA Conference 2022?

Molecular Partners is presenting data on MP0533, a T-cell engager that targets tumor-associated antigens, which underscores their advancement in cancer treatment research.

When is the European Hematology Association Conference where Molecular Partners will present?

The European Hematology Association Conference will take place from June 9-12, 2022, in Vienna.

What presentations will be made by Novartis at upcoming conferences?

Novartis will present preclinical data on ensovibep, a DARPin therapeutic candidate for COVID-19, during the ASM Microbe Conference from June 9-13, 2022.

How does Molecular Partners' work on DARPin therapeutics impact their stock, MOLN?

Progress in DARPin therapeutics could attract investor interest and potentially positively impact the stock price of MOLN.